Drugs / AZD7451
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01468324 | Oct 2011 → Apr 2014 | glioblastoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD7451 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01468324 ↗ |
| Known as | Utatrectinib | ChEMBL registry synonym — accepted as the source's own label CHEMBL3659497 ↗ |
| Action | Inhibit | “Neurotrophic tyrosine kinase receptor type 2 inhibitor” CHEMBL3659497 ↗3“AZD7451 is a first-in-class inhibitor of Trk.” NCT01468324 ↗ “Nerve growth factor receptor Trk-A inhibitor” CHEMBL3659497 ↗ “NT-3 growth factor receptor inhibitor” CHEMBL3659497 ↗ |
| Modality | Small molecule | — CHEMBL3659497 ↗ |
| Route | Oral | “Participants will take AZD7451 daily by mouth for 28-day cycles of treatment.” NCT01468324 ↗ |
| Target | NTRK1 | “Nerve growth factor receptor Trk-A inhibitor” CHEMBL3659497 ↗ |
| Target | NTRK2 | “Neurotrophic tyrosine kinase receptor type 2 inhibitor” CHEMBL3659497 ↗ |
| Target | NTRK3 | “NT-3 growth factor receptor inhibitor” CHEMBL3659497 ↗ |